Cargando…
Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
BACKGROUND AND OBJECTIVE: Tolvaptan, an oral vasopressin V2 receptor antagonist, has been widely used for the treatment of patients with cirrhosis and ascites. However, its efficacy in patients with renal dysfunction remains unknown. The objective of this study was to investigate the efficacy and sa...
Autores principales: | Arase, Yoshitaka, Kagawa, Tatehiro, Tsuruya, Kota, Sato, Hirohiko, Teramura, Erika, Anzai, Kazuya, Hirose, Shunji, Deguchi, Ryuzo, Shiraishi, Koichi, Mine, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510826/ https://www.ncbi.nlm.nih.gov/pubmed/30284699 http://dx.doi.org/10.1007/s40261-018-0714-5 |
Ejemplares similares
-
First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023) -
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Arase, Yoshitaka, et al.
Publicado: (2019) -
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B
por: Nagata, Naruhiko, et al.
Publicado: (2016) -
Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases
por: Arase, Yoshitaka, et al.
Publicado: (2019) -
Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma
por: Mizukami, Hajime, et al.
Publicado: (2012)